‹ Back to screener

BIOCON.NS Biocon Ltd.

Healthcare

Price history

2023-08-22 ₹260.00
2026-08-21 ₹412.90
Change over window +58.81%

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical indicators

ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Delivery volume

Latest (2026-08-28) 51.3%
Trailing 20-day average 50.8%
Date Traded Qty Delivery Qty Delivery %
2026-08-28 2187557 1122493 51.31%
2026-08-27 1713404 794668 46.38%
2026-08-26 2245587 1365829 60.82%
2026-08-25 3087232 1524343 49.38%
2026-08-24 1761155 997043 56.61%
2026-08-21 2225359 1265620 56.87%
2026-08-20 1981150 1168451 58.98%
2026-08-19 1683297 795512 47.26%
2026-08-18 2691030 1185755 44.06%
2026-08-17 3190219 1516740 47.54%
2026-08-14 3992844 2325866 58.25%
2026-08-13 4627924 2515565 54.36%
2026-08-12 3793310 1866520 49.21%
2026-08-11 1959909 1022637 52.18%
2026-08-10 2289723 1165819 50.92%
2026-08-07 5265823 2498011 47.44%
2026-08-06 10929015 2834028 25.93%
2026-08-05 3296172 1789073 54.28%
2026-08-04 2478487 1183448 47.75%
2026-08-03 3389704 1926712 56.84%

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers BIOCON.NS to fetch more history.

Insider trading activity

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake
05 Apr 2024 NEHAL VORA Employees/Designated Employees Pledge Pledge Creation 61827 15864808 0.04% XBRL
04 Apr 2024 SIVANANDAM K - Pledge Pledge Creation 7328 1880365 0.00% XBRL
02 Apr 2024 KIRAN KUMAR GANDHIRAJAN Employees/Designated Employees Sell Market Sale 19998 5286351 0.01% XBRL
02 Apr 2024 Akhilesh Nand Employees/Designated Employees Sell Market Sale 11000 2866050 0.01% XBRL
19 Mar 2024 SHASHI KANT TIWARI Employees/Designated Employees Buy ESOP 6792 1709207 0.00% XBRL
05 Mar 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 1000 275800 0.01% XBRL
05 Mar 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 2000 541900 0.01% XBRL
05 Mar 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 5000 1415000 0.01% XBRL
29 Feb 2024 SANTOSH GOVINDRAO KATTI - Buy ESOP 20500 5628275 0.00% XBRL
29 Feb 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 1000 278550 0.01% XBRL
29 Feb 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 1000 277500 0.01% XBRL
29 Feb 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 1000 277350 0.01% XBRL
29 Feb 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 2000 558400 0.01% XBRL
27 Feb 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 5000 1362500 0.01% XBRL
27 Feb 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 2000 540900 0.01% XBRL
26 Feb 2024 Gayatri Nayak Employees/Designated Employees Sell Market Sale 5000 1357500 0.00% XBRL
23 Feb 2024 INDRANIL SEN Employees/Designated Employees Buy ESOP 94071 26452765 0.01% XBRL
23 Feb 2024 INDRANIL SEN Employees/Designated Employees Sell ESOP 39000 10528405 0.00% XBRL
23 Feb 2024 Biocon India Limited Employees Welfare Trust Other Sell ESOP 39000 10528405 0.33% XBRL
22 Feb 2024 MUKESH KAMATH K Employees/Designated Employees Sell Market Sale 5000 1494000 0.01% XBRL

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers BIOCON.NS to fetch more.

Ratios as of FY2025-26 (Annual) · Price ₹415.55 INR (live) · fetched 2026-08-23 21:39 price stale

Extract this company (financials + ratios + citations): CSV · XLSX

Ratios

P/E
174.69
P/E = Price / EPS
P/E (Price to Earnings)

What the market pays today for one rupee of last year's profit.

P/E = Price ÷ (Net Income ÷ Diluted Shares Outstanding)

P/E divides the share price by earnings per share. If a share costs ₹300 and the company earned ₹15 per share, the P/E is 20 — buyers are paying twenty rupees for each rupee of annual profit.

A high P/E is not automatically 'expensive' and a low one is not automatically 'cheap'. A high number can mean the market expects profits to grow, or that the last year's profit was unusually low. A low number can mean the market expects profits to fall. P/E on its own says nothing about whether a price is justified — it is a starting question, not an answer.

P/E is undefined when a company made a loss, because dividing by a negative or zero profit produces a figure that cannot be read the normal way. StockProof shows N/A rather than a negative P/E.

In StockProof StockProof computes this from the latest cached price and the net income and diluted share count in the most recent filing on file. The historical P/E chart uses a different basis — filed annual EPS against an adjusted closing price — so the two figures are not directly comparable and are never differenced.

Introduction to the price-to-earnings ratio ↗ Khan Academy — external link, not StockProof content

Source trace
P/E = Price / (ProfitOrLossAttributableToOwnersOfParent / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹415.55 / (₹3,856,000,000 / 1,621,000,000 shares) = ₹415.55 / ₹2.38 EPS
FY2025-26 · Annual filing
ROE
1.13%
ROE = Net Income / Shareholder Equity
ROE (Return on Equity)

How much profit the company generated per rupee of shareholders' own money.

ROE = Net Income ÷ Shareholder Equity

ROE divides net income by shareholders' equity — the money owners have put in plus the profits kept in the business rather than paid out. An ROE of 18% means the business turned every ₹100 of owners' capital into ₹18 of annual profit.

ROE is flattered by debt. A company that funds itself heavily with borrowing has less equity in the denominator, so the same profit produces a higher ROE. Two companies with identical ROE can carry completely different risk, which is why ROE is read next to Debt/Equity rather than on its own — and why the DuPont decomposition below exists.

In StockProof Equity here is the figure filed in the most recent annual or quarterly statement. For banks and NBFCs the composite differs from a manufacturer's, which is why the source-trace line under each figure names the exact filed line item used.

DuPont decomposition

Splits ROE into three parts, so you can see whether it came from margin, efficiency, or debt.

ROE = (Net Income ÷ Revenue) × (Revenue ÷ Total Assets) × (Total Assets ÷ Equity)

The same ROE can be produced three very different ways. DuPont breaks it into Net Profit Margin × Asset Turnover × Equity Multiplier — how much profit each rupee of sales leaves, how much sales each rupee of assets generates, and how many rupees of assets sit on each rupee of equity.

A luxury brand reaches its ROE through margin. A supermarket reaches a similar ROE through turnover on thin margins. A leveraged lender reaches it through the equity multiplier. Only the third of those raises ROE by raising risk, and a single ROE number cannot tell you which of the three you are looking at.

This is why a rise in ROE is worth taking apart before it is treated as good news: an ROE that improved because the company borrowed more is a different fact from an ROE that improved because margins widened.

In StockProof StockProof does not yet render the three-way split as its own view — it is on the roadmap. The explanation is here because it is the right way to read the ROE figure shown beside it.

Source trace
ROE = ProfitOrLossAttributableToOwnersOfParent / EquityAttributableToOwnersOfParent → ₹3,856,000,000 / ₹340,318,000,000 = 1.13%
FY2025-26 · Annual filing
Debt/Equity
0.44
Debt/Equity = Total Debt / Shareholder Equity
Debt / Equity

How many rupees the company has borrowed for each rupee of owners' money.

Debt / Equity = Total Debt ÷ Shareholder Equity

A Debt/Equity of 0.5 means fifty paise of borrowing per rupee of equity; a figure of 2.0 means two rupees of borrowing per rupee of equity. It is the plainest single measure of how much of the business is funded by lenders rather than owners.

Borrowing is not itself a fault. It magnifies outcomes in both directions: the same leverage that lifts returns in a good year deepens losses in a bad one, and interest has to be paid whether or not the year was good. What counts as a lot depends entirely on the industry — a utility with contracted cash flows and a cyclical commodity producer are not comparable on this number.

Financial companies are the clearest case: for a bank or an NBFC, borrowing IS the raw material of the business, so a Debt/Equity that would be alarming for a manufacturer is ordinary for a lender.

In StockProof Both figures come from the same filing, so the ratio is internally consistent even when the filing itself is restated later.

Source trace
Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹148,247,000,000 / ₹340,318,000,000 = 0.44
FY2025-26 · Annual filing
Current Ratio
1.22
Current Ratio = Current Assets / Current Liabilities
Source trace
Current Ratio = CurrentAssets / CurrentLiabilities → ₹171,798,000,000 / ₹140,692,000,000 = 1.22
FY2025-26 · Annual filing
ROCE
3.77%
ROCE = EBIT / (Shareholder Equity + Total Debt)
ROCE (Return on Capital Employed)

Return on ALL the long-term money in the business, borrowed as well as owned.

ROCE = EBIT ÷ (Total Equity + Total Debt)

ROCE divides operating profit (EBIT) by capital employed — equity plus debt. Where ROE asks what the owners earned, ROCE asks what the whole business earned on every rupee financed into it, whoever supplied that rupee.

Because the denominator includes debt, ROCE is not flattered by borrowing the way ROE is. That makes it the more comparable figure across companies with different capital structures, and the usual first check on whether a business is genuinely productive or merely leveraged.

A useful reference point is the company's own cost of borrowing: a business earning a ROCE below what it pays on its debt is consuming value on each additional rupee it employs.

In StockProof For lenders (banks, NBFCs, housing finance companies) the balance sheet has no current/non-current split and Finance Costs are close to a core operating cost rather than a financing item. StockProof still shows ROCE for those filers but prints an explicit caveat beside it — that caveat is not part of Learning Mode and shows whether or not this mode is on.

Source trace
ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹18,411,000,000 / (₹340,318,000,000 + ₹148,247,000,000) = 3.77%
FY2025-26 · Annual filing
Dividend Yield
0.13%
Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace
Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹908,000,000 / 1,621,000,000 shares) / ₹415.55 = ₹0.56 / ₹415.55
FY2025-26 · Annual filing

Growth & earnings trend

Revenue & Profit CAGR

Revenue (3y, 7.0y actual) 17.4%
Net Profit (3y) -11.5%
Revenue (5y, 7.0y actual) 17.4%
Net Profit (5y) -11.5%
Revenue (10y, 7.0y actual) 17.4%
Net Profit (10y) -11.5%

Operating Margin Trend

Eroding

FY2018-19 19.8%
FY2019-20 19.0%
FY2020-21 16.8%
FY2021-22 16.7%
FY2022-23 15.9%
FY2023-24 17.6%
FY2024-25 17.6%
FY2025-26 10.9%

ROCE Trajectory

FY2018-19 N/A
FY2019-20 N/A
FY2020-21 N/A
FY2021-22 N/A
FY2022-23 4.4%
FY2023-24 6.3%
FY2024-25 5.9%
FY2025-26 3.6%

Earnings Quality

No persistent gap detected

Net Profit CAGR -12.18% vs CFO CAGR 14.10% over 4.0y (2022-03-31 → 2026-03-31); most recent year: Net Profit -61.95% vs CFO -50.90%

Sector-Relative Percentile (Healthcare)

ROE 7th
ROCE 4th
Debt/Equity 17th
P/E 2th

Quarterly trend

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q4 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q2 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹3,917.10 Cr. ₹3,432.90 Cr. ₹3,590.40 Cr. ₹3,821.40 Cr. ₹4,417.00 Cr. ₹3,941.90 Cr. ₹4,295.50 Cr. ₹4,173.00 Cr. ₹4,516.60 Cr. ₹4,336.00 Cr. RevenueFromOperations
Net Profit ₹135.50 Cr. incl. minority ₹222.90 Cr. ₹659.70 Cr. incl. minority ₹861.80 Cr. ₹-16.00 Cr. incl. minority ₹27.10 Cr. ₹25.10 Cr. incl. minority ₹81.10 Cr. ₹344.50 Cr. incl. minority ₹459.40 Cr. ₹31.40 Cr. incl. minority ₹89.20 Cr. ₹84.50 Cr. incl. minority ₹132.80 Cr. ₹143.80 Cr. incl. minority ₹-51.80 Cr. ₹125.90 Cr. incl. minority ₹198.60 Cr. ₹141.10 Cr. incl. minority ₹136.80 Cr. ProfitOrLossAttributableToOwnersOfParent

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers BIOCON.NS to fetch more.

Source document — income statement (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

ProfitOrLossAttributableToOwnersOfParent3856000000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital1621000000.0
Source document — balance sheet (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

CurrentAssets171798000000.0
CurrentLiabilities140692000000.0
EquityAttributableToOwnersOfParent340318000000.0
BorrowingsCurrent + BorrowingsNoncurrent148247000000.0

My notes